Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
expanded activated NK cells
- Development stage
- Unknown
- Lead developer
- Artiva Biotherapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Intratumoral, Intrathecal
01
Overview
Expanded activated (EA) NK cells are a form of cellular immunotherapy that involves the isolation, ex vivo expansion, and activation of natural killer cells. These cells are part of the innate immune system and can recognize and kill abnormal cells including cancer cells and virus-infected cells without prior sensitization. The expansion process typically uses cytokines like IL-15, IL-2, and CD137L to significantly increase NK cell numbers and enhance their cytotoxic capabilities. EA NK cells can be used in both autologous (patient's own cells) and allogeneic (donor-derived) settings, with the latter offering potential as an 'off-the-shelf' therapy. They can be administered alone or in combination with monoclonal antibodies to enhance antibody-dependent cellular cytotoxicity (ADCC).
- Brand names
- AlloNKSNK01SNK-01SNK 01SNK02SNK-02SNK 02troculeucel
- Other names
- CIML NK cells
02
Targets
MICB (Major histocompatibility complex class i-related protein B)NKG2DL (NKG2D ligand family)IgG Fc (Immunoglobulin G Fc region)
Beyond the preview
Go deeper on expanded activated NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on expanded activated NK cells.